Emory and NIH continue public-private partnership advancing Alzheimer’s research
The National Institutes of Health is launching the next version of AMP AD (Accelerating Medicines Partnership Alzheimer’s Disease), a public-private partnership that takes an open science, big data approach to identifying biological targets for therapeutic intervention.
The National Institute on Aging will lead research efforts for AMP AD 2.0 and has pledged to contribute $61.4 million over five years. This includes funding six multi-institutional, cross-disciplinary academic research teams, including the team at Goizueta Alzheimer’s Research Center at Emory University, along with a data coordinating center at Sage Bionetworks.
Emory researchers served as a founding academic team for the first iteration of the AMP AD when the initiative began in 2014. Led by Allan Levey and Nicholas T. Seyfried, Emory investigators will play an integral role in AMP AD 2.0 as it seeks to support new technologies,
Depresión: Estudio descubre genes que podrían causar la enfermedad
sdpnoticias.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdpnoticias.com Daily Mail and Mail on Sunday newspapers.
Avance en la búsqueda de nuevos tratamientos para la depresión
infosalus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infosalus.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: In their lab at the Atlanta VA and Emory University, Dr. Thomas Wingo and Dr. Aliza Wingo (foreground) have found genes and corresponding proteins that could open doors for new. view more
Credit: Lisa Pessin
Using an innovative protein-based approach, researchers at the Atlanta Veterans Affairs Medical Center and nearby Emory University have found genes and corresponding proteins that could point the way to new depression treatments.
Using a proteome-wide association study (PWAS) that integrated genome-wide association study (GWAS) data with human brain proteomic and genetic data, researchers have identified 19 genes that may lead to depression by altering brain protein levels. They also pinpointed 25 such proteins that offer promise as potential targets for new depression treatments.